Is A2M Better Than PRP?

Quick Answer

It depends on your goal. For short-term pain and inflammation, A2M is the better fit, comparable to a corticosteroid injection without the cartilage downsides, and trending broader than PRP at twelve weeks in the only head-to-head clinical trial. For longer-term tissue repair, PRP is the better choice because its growth factors drive the proliferative phase of healing that rebuilds tissue; long-term studies on A2M are limited.

If you are looking at Alpha-2-Macroglobulin (A2M) and platelet-rich plasma (PRP) for joint pain, the two are often compared as if you have to pick one. They actually do different jobs in different phases of joint healing. This post breaks down what the head-to-head research shows and why mixing them in one injection backfires. Dr. Mareshah Dunning, NMD, treats both at Solutions Regenerative Medicine in East Valley, Arizona.

What’s the Short Answer?

Only one randomized clinical trial has directly compared A2M, PRP, and corticosteroid injection for knee osteoarthritis (Thompson et al., 2024, PMID: 39259950). At twelve weeks, A2M outperformed both PRP and corticosteroid on a per-measure basis:

A2M produced statistically significant improvements from baseline on four patient-reported measures: pain, function, knee quality of life, and activity level.
The corticosteroid group produced a statistically significant improvement on only one patient-reported measure (a knee function rating).
PRP did not produce statistically significant improvements from baseline on any of the measured outcomes.

Beyond the head-to-head trial, PRP has stronger evidence over a longer time frame. A 2025 systematic review and meta-analysis of twenty-eight randomized trials (3,246 patients) found that PRP’s clinical improvements peak around three months and are sustained through twelve months in knee osteoarthritis (Wang & Yao, 2025, PMID: 41107915). The A2M literature does not yet have peer-reviewed clinical data beyond the twelve-week mark. The takeaway: A2M was the only treatment in the head-to-head trial to produce reliable improvements across multiple patient-reported measures at twelve weeks, while PRP shows sustained benefit at twelve months in the broader literature. The two treatments do different jobs on different timelines.

How Are A2M and PRP Different?

A2M and PRP are best understood by the phase of healing each one is suited for. Joint and connective tissue healing moves through three phases: an inflammatory phase, a proliferative phase, and a remodeling phase. A2M and PRP act on different points in that arc. A2M acts primarily in the inflammatory phase. It binds and clears the cytokines and cartilage-degrading enzymes (IL-1β, IL-6, MMP-13, ADAMTS-4/-5) that keep a joint stuck in chronic inflammation; in vitro work has shown A2M binds IL-1β directly and blocks the downstream NF-κB pathway in chondrocytes (Sun et al., 2023, PMID: 35451533). PRP acts primarily in the proliferative and remodeling phases, with some inflammatory-phase activity depending on the preparation. It delivers a concentrated dose of platelets, growth factors, and other healing proteins, and forms a fibrin scaffold where repair cells can attach, migrate, and rebuild. A2M and PRP are not really competitors; they do different jobs at different points in healing.

	A2M	PRP
What it is	Concentrated cytokine and enzyme trap from your own blood	Concentrated platelets, growth factors, and healing proteins from your own blood
Phase of healing	Inflammatory phase	Inflammatory (amount depends on formulation), proliferative, and remodeling phases
Mechanism	Traps IL-1, IL-6, MMP-13, and the aggrecanases ADAMTS-4 and ADAMTS-5	Delivers concentrated growth factors and forms a healing scaffold where repair cells can attach, migrate, and rebuild tissue
Best fit	Knee, hip, shoulder, facet joints, nerve-related pain, autoimmune flares	Osteoarthritis, tendinopathies, ligament injuries
Onset of relief	Days to weeks; steady through six to twelve weeks	4 to 8 weeks initial improvement; peak around 2 to 3 months; relief often lasts about a year
Combined in one syringe	No: would trap the enzymes PRP-driven remodeling needs	No: A2M would inhibit the matrix metalloproteinases that PRP-driven remodeling depends on
Used together, sequenced	Yes: A2M first to calm inflammation	Yes: PRP 3 to 4 weeks after A2M, once the inflammatory phase has resolved

Why A2M and PRP Should Be Sequenced, Not Combined

Many regenerative medicine clinics and online sources promote A2M + PRP combination injections as synergistic. Mechanistically, the combined-injection approach is at odds with how each treatment is designed to work.

Common Misconception

“A2M and PRP work best when combined in one injection.”

Many clinic websites promote A2M + PRP combination injections as synergistic. Mechanistically, this approach is at odds with how each treatment is designed to work and likely undermines both. The two are better sequenced than mixed.

PRP-driven repair depends on the same enzymes that A2M is designed to trap. Matrix metalloproteinases (MMPs) and the aggrecanases are not only destructive in chronic inflammation; in the proliferative and remodeling phases, they are the controlled tools tissue uses to rebuild itself. A2M does not distinguish between a “pathological” MMP and a “useful” one. It binds both. Mixing A2M and PRP in one syringe is likely to neutralize the MMPs that PRP-driven repair depends on, blunting the very mechanism PRP is intended to drive.

A2M and PRP can still be used together; the key is sequencing rather than mixing. At Solutions Regenerative Medicine in East Valley, Arizona, Dr. Dunning gives A2M first to act on the inflammatory phase. Approximately three to four weeks later, after most of the injected A2M is expected to have been processed and cleared through lymphatic drainage and macrophage uptake, she gives the PRP injection (or another advanced orthobiologic such as bone marrow aspirate concentrate or micronized fat if the treatment plan calls for it). With the inflammatory phase resolved, the regenerative therapy’s growth factors and healing proteins land in the environment they are designed to work in. Dr. Dunning adjusts the exact interval based on each patient’s response and joint condition.

When Should You Choose A2M, PRP, or Both?

The right choice depends on where your joint is in the inflammation-versus-repair spectrum, what you are treating, and your goals.

Choose A2M if your joint has been swollen, stiff, and painful over a long stretch with limited movement. That pattern usually means the joint is stuck in chronic inflammation, and A2M targets the cytokines and enzymes driving it. A2M is also a good fit if you are in a lot of pain and do not want to start with a more aggravating injectable, if you want an anti-inflammatory option drawn from your own blood instead of corticosteroid, or as the first step when your provider plans a regenerative treatment afterward.

Choose PRP if your goal is to actively rebuild tissue. Common fits include osteoarthritis, tendinopathies such as chronic Achilles tendinopathy or tennis elbow, a partial rotator cuff tear, or a partial ligament tear. PRP’s growth factors, healing proteins, and fibrin scaffold suit the active-repair scenario.

Choose both, sequenced if your joint has a heavy inflammatory load AND a structural repair need, for example, a knee with chronic synovitis along with a cartilage or meniscus goal. A2M first to calm the inflammation; PRP three to four weeks later to drive the repair.

Why Choose Dr. Dunning at Solutions Regenerative Medicine?

Choosing between A2M and PRP, or knowing when to use both, depends on understanding exactly where your joint is in the healing process. That is the decision Dr. Mareshah Dunning, NMD, is trained to make. She performs every regenerative injection under ultrasound or fluoroscopic (real-time X-ray) guidance. Fluoroscopy in particular is rarely used in regenerative medicine outside of providers trained as interventionalists. Her fluoroscopy training came from a residency under interventional anesthesiologist and general surgeon Dr. Klee Bethel, and her musculoskeletal ultrasound training was completed under Richard Kates, RMSKS, whose own mentors were RMSK pioneers Colin Rigney, DPT, and Wayne Smith, DPT. She also goes beyond mainstream practice, digging into the literature, mechanistic science, and holistic health to bring patients the best available technology and results. Solutions Regenerative Medicine serves East Valley, Arizona.

Frequently Asked Questions

Can I get A2M and PRP at the same visit?

No. A2M and PRP target different phases of joint healing, and combining them in one syringe is likely to have A2M bind the enzymes that PRP-driven repair depends on. When both are part of a treatment plan at Solutions Regenerative Medicine in East Valley, Arizona, Dr. Dunning gives them at separate visits, typically three to four weeks apart, with A2M first.

Are A2M or PRP injections covered by insurance?

Both A2M and PRP are generally not covered by insurance. The injectable products themselves will not be reimbursed even with a superbill, though the office visit and injection administration may qualify for partial reimbursement under out-of-network coverage with private insurance. Medicare and Medicaid do not cover these treatments. Health Savings Accounts (HSAs) can often be applied toward the cost.

Which one is right for me?

It comes down to what you want the treatment to do. A2M is the choice when the goal is to decrease inflammation. PRP is the choice when the goal is to promote tissue repair. Both work across the same joint and connective-tissue conditions, and when both goals apply, the two can be sequenced (A2M first, PRP three to four weeks later). Dr. Dunning evaluates which approach fits your goals during the consultation.

Wondering whether A2M, PRP, or a sequenced combination is right for you?

Dr. Mareshah Dunning at Solutions Regenerative Medicine in East Valley, Arizona offers personalized consultations to evaluate your condition and recommend the most appropriate regenerative approach. Book a consultation with Dr. Dunning or call (480) 995-9131.

Explore our full range of regenerative injection therapies →